Vertex Eyes Triple Glory After Hat Trick of CF Approvals

 
• By Kevin Grogan

Symdeko, which will have a wholesale price of $292,000 per year, has got the green light in the US, adding to Vertex' already-approved cystic fibrosis treatments Kalydeco and Orkambi. Now, focus will shift onto its role in potential triple combinations for the disease.

Soccer
Back of the net: Vertex has gained its third US approval for a CF therapy • Source: Shutterstock

More from Rare Diseases

More from Scrip